Navigation Links
LA BioMed investigators uncover new advancements in cardiovascular medicine
Date:2/21/2012

LOS ANGELES (Feb. 21, 2012) With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) Dr. Matthew Budoff and Dr. Ronald Oudiz continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

"Our research is aimed at achieving earlier detection of heart disease, especially in asymptomatic patients," said Dr. Budoff. "We've been very fortunate to have received such overwhelming support from different entities, which has enabled us to continue our research in cardiovascular medicine."

"As the nation focuses on heart health this month, we continue to aggressively find ways to decrease the chances of heart failure and subsequently death - for patients with pulmonary hypertension, a rare disorder that results in progressive heart failure and death," said Dr. Oudiz.

Dr. Budoff has been a thought leader in coronary artery calcium and computed tomographic (CT) angiography over the last 20 years. Dr. Budoff's expertise ranges from coronary artery calcium and CT angiography, to venous imaging, aortic imaging, and ventricular and atrial imaging. He and his staff have worked closely with partners in device manufacturing to assess the adequacy of different techniques, acting as a core lab for studies including heart failure devices, mitral valve and aortic valve repair techniques and devices, pacemakers (both wireless and biventricular), and stents (coronary and aortic), among others.

Currently, Dr. Budoff and his staff are working on a study to assess whether using a garlic extract can have a significant impact on the buildup of plaque, which has been known to cause heart attacks. They are also working on several ongoing studies looking at interactions of testosterone, a study on diabetes, and a study looking at heart disease among persons with lung disease. Additionally, Dr. Budoff serves as Director of Cardiac CT at the Diagnostic and Wellness Imaging Center, an accredited center of excellence that serves as the exclusive cardiac imaging center for fire and police departments in Los Angeles County, and where experts in medicine come for their cardiac imaging.

Dr. Oudiz is a pioneer in the field of pulmonary arterial hypertension (PAH), having received the 2011 Award for Excellence from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease. PAH is an increase in blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries that can lead to shortness of breath, dizziness or fainting. It is a rare form of pulmonary hypertension (PH) that affects between 500-1,000 people each year - or 1 or 2 people out of one million people worldwide per year - most of whom are young women between the ages of 20 and 40.

Currently, Dr. Oudiz is a member of a steering committee for a study that is looking at a new heart failure drug made by Bayer, riociguat, that hopes to further improve symptoms beyond usual care. The study is designed to assess whether increasing oral doses of riociguat are safe and improve the well-being, symptoms, and outcome in patients with PH associated with heart failure due to left ventricular systolic dysfunction. He and his colleagues are also involved in another study of a drug for PH called prostacyclin, one of the most potent drugs for PH. This research is focused on finding a way for patients to take prostacyclin in an oral form, where currently prostacyclin is given via continuous infusion (injection) or inhalation.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
2. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
3. First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University
4. Seattle BioMed Offers the Gift of Hope for Mother's Day
5. LA BioMed awarded research grant to study HIV prevention gel
6. Cambridge Healthtech Institute to Host Its Second Annual Collaborative Innovation in Biomedicine Conference
7. New Diagnostic Testing Company, Blue Ocean Biomedical, Specializes In Automated, Load & Go Cell Analysis Systems For Immune Monitoring
8. Manmade antibodies hold biomedical promise
9. Applied nuclear physics for biomedicine, nuclear security and basic science
10. Blue Ocean Biomedical Opens New Manufacturing Facility In Miramar, FL
11. Team led by LA BioMed scientist develops novel approach to study neurological disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: